SG11202003307XA - Inhibitors of mutant egfr family tyrosine-kinases - Google Patents

Inhibitors of mutant egfr family tyrosine-kinases

Info

Publication number
SG11202003307XA
SG11202003307XA SG11202003307XA SG11202003307XA SG11202003307XA SG 11202003307X A SG11202003307X A SG 11202003307XA SG 11202003307X A SG11202003307X A SG 11202003307XA SG 11202003307X A SG11202003307X A SG 11202003307XA SG 11202003307X A SG11202003307X A SG 11202003307XA
Authority
SG
Singapore
Prior art keywords
kinases
inhibitors
mutant egfr
family tyrosine
egfr family
Prior art date
Application number
SG11202003307XA
Inventor
Prasad Chaturvedula
Prasad Kolli
Original Assignee
Spectrum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrum Pharmaceuticals Inc filed Critical Spectrum Pharmaceuticals Inc
Publication of SG11202003307XA publication Critical patent/SG11202003307XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/027Organoboranes and organoborohydrides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202003307XA 2017-10-18 2018-10-18 Inhibitors of mutant egfr family tyrosine-kinases SG11202003307XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762574110P 2017-10-18 2017-10-18
PCT/US2018/056516 WO2019079599A1 (en) 2017-10-18 2018-10-18 Inhibitors of mutant egfr family tyrosine-kinases

Publications (1)

Publication Number Publication Date
SG11202003307XA true SG11202003307XA (en) 2020-05-28

Family

ID=66174232

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003307XA SG11202003307XA (en) 2017-10-18 2018-10-18 Inhibitors of mutant egfr family tyrosine-kinases

Country Status (17)

Country Link
US (2) US20200261455A1 (en)
EP (1) EP3697416A4 (en)
JP (1) JP2021500350A (en)
KR (1) KR20200072498A (en)
CN (1) CN111542322A (en)
AR (1) AR113451A1 (en)
AU (1) AU2018353142A1 (en)
BR (1) BR112020007783A2 (en)
CA (1) CA3078654A1 (en)
IL (1) IL274015A (en)
MX (1) MX2020004036A (en)
PH (1) PH12020550259A1 (en)
RU (1) RU2020117315A (en)
SG (1) SG11202003307XA (en)
TW (1) TW201922726A (en)
UY (1) UY37935A (en)
WO (1) WO2019079599A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210066841A (en) * 2018-09-21 2021-06-07 스펙트럼 파마슈티컬즈 인크 Novel Quinazoline EGFR Inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0207323D0 (en) * 2002-03-28 2002-05-08 Astrazeneca Ab Compounds
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
WO2005026151A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
GB0321620D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
WO2010129053A2 (en) * 2009-05-05 2010-11-11 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
US9034885B2 (en) * 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
CN104761544B (en) * 2014-01-03 2019-03-15 北京轩义医药科技有限公司 The selective depressant of the important mutant of clinic of EGFR tyrosine kinase
DK3157916T3 (en) * 2014-06-19 2019-03-18 Ariad Pharma Inc HETEROARYL COMPOUNDS FOR CHINESE INHIBITION
KR102327053B1 (en) * 2017-03-16 2021-11-17 기초과학연구원 Quinazoline, Quinoline Derivatives and Their Use as EGFR Kinase Inhibitors

Also Published As

Publication number Publication date
US20200261455A1 (en) 2020-08-20
IL274015A (en) 2020-06-30
UY37935A (en) 2020-03-31
EP3697416A1 (en) 2020-08-26
BR112020007783A2 (en) 2020-10-20
WO2019079599A8 (en) 2020-06-25
TW201922726A (en) 2019-06-16
JP2021500350A (en) 2021-01-07
WO2019079599A1 (en) 2019-04-25
US20230106731A1 (en) 2023-04-06
CA3078654A1 (en) 2019-04-25
CN111542322A (en) 2020-08-14
RU2020117315A3 (en) 2022-04-25
AR113451A1 (en) 2020-05-06
KR20200072498A (en) 2020-06-22
AU2018353142A1 (en) 2020-05-07
MX2020004036A (en) 2021-01-15
EP3697416A4 (en) 2021-06-02
RU2020117315A (en) 2021-11-17
PH12020550259A1 (en) 2021-03-01

Similar Documents

Publication Publication Date Title
EP3541932A4 (en) Inhibitors of crispr-cas9
EP3600318A4 (en) Methods of using ehmt2 inhibitors
IL270844A (en) Novel inhibitors of map4k1
IL279791A (en) Inhibitors of cyclin-dependent kinases
IL281939A (en) Inhibitors of vap-1
EP4069212A4 (en) Inhibitors of hif-2alpha
HUE062460T2 (en) Inhibitors of trpc6
EP3801503A4 (en) Inhibitors of sarm1
PT3458448T (en) Methods of using fasn inhibitors
HK1248684A1 (en) Usp7 inhibitor compounds and methods of use
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
EP3265093A4 (en) Tricyclic kinase inhibitors of melk and methods of use
IL281815A (en) Inhibitors of vap-1
IL276592A (en) Derivatives of sobetirome
EP3801499A4 (en) Inhibitors of sarm1
EP3894768C0 (en) Methods of cryo-curing
GB2573065B (en) Optimization of ranging measurements
EP3801500A4 (en) Inhibitors of sarm1
EP3801525A4 (en) Inhibitors of prolyl-trna-synthetase
IL274015A (en) Inhibitors of mutant egfr family tyrosine-kinases
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases
IL277866A (en) Substituted aminothiazoles as inhibitors of nucleases
IL277869A (en) Substituted propanamides as inhibitors of nucleases
IL264173A (en) Solid forms of ttk inhibitor
SG11202101817UA (en) Methods of inhibition